ID   JON
AC   CVCL_M891
SY   JO'N; J'O.N.; J.O.N.; J.O.'N.; JO N; JO-N; J ON
DR   cancercelllines; CVCL_M891
DR   Cosmic; 715706
DR   Cosmic; 760472
DR   Cosmic; 845567
DR   Cosmic; 1016891
DR   Cosmic; 1285121
DR   Cosmic; 1285999
DR   Cosmic; 2037948
DR   Cosmic; 2050447
DR   Cosmic; 2057452
DR   Cosmic; 2444249
DR   Cosmic; 2686099
DR   GEO; GSM136254
DR   GEO; GSM763025
DR   Progenetix; CVCL_M891
DR   Wikidata; Q54899036
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=11921286;
RX   PubMed=15846775;
RX   PubMed=16885334;
RX   PubMed=24018021;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25997541;
RX   PubMed=26621286;
RX   PubMed=27270441;
RX   PubMed=29732388;
WW   Info; Synapse; Bladder Cancer exome; https://www.synapse.org/Synapse:syn4970200
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (PubMed=27270441).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=27270441).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=27270441
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 14
ST   D16S539: 11,13
ST   D5S818: 11,12
ST   D7S820: 7,8
ST   TH01: 6,9.3
ST   TPOX: 8,9
ST   vWA: 18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 10-04-25; Version: 22
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=11921286; DOI=10.1002/gcc.10050;
RA   Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N.,
RA   Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.;
RT   "Molecular genetic analysis of chromosome 9 candidate tumor-suppressor
RT   loci in bladder cancer cell lines.";
RL   Genes Chromosomes Cancer 34:86-96(2002).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182;
RA   Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J.,
RA   Carrato A., Tardon A., Serra C., Real F.X.;
RT   "PIK3CA mutations are an early genetic alteration associated with
RT   FGFR3 mutations in superficial papillary bladder tumors.";
RL   Cancer Res. 66:7401-7404(2006).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:e84411.1-e84411.11(2013).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3; PMCID=PMC4470036;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=26621286; DOI=10.1186/s12864-015-2227-4; PMCID=PMC4681452;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a
RT   genomic resource for functional studies.";
RL   BMC Genomics 16:1019.1-1019.2(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172; PMCID=PMC5140783;
RA   Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K.,
RA   Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//